REMARKS

Claims 1-29, as amended, and new claims 30-31 are pending for the Examiner's consideration in view of the Information Disclosure Statement submitted herewith. Applicants note that claim 26 appears as a second claim 25 in the original application and in the publication. This amendment corrects the typographical error to claim 26, and amends claims 27-28 to properly depend from claim 26. New claims 30-31 recite the new trifluoroacetate and sulfate salts of Teverelix (See, e.g., Specification at page 6, lines 1-8). Thus, no new matter is believed to have been added by the amendments or the addition of these new claims.

Applicants now believe all claims to be in condition for entry and allowance. Should the Examiner not agree with this position, a telephone or personal interview is requested to resolve any remaining issues and expedite allowance of this application.

Respectfully submitted,

For: Allan A. Fanucci

WINSTON & STRAWN LLP Customer Number: 28765

202-371-5770